trial · primary record
HER3-DXd
Non-Small Cell Lung Cancer (NSCLC)
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 246 |
| Primary completion | 2027-12-14 |
| Primary endpoint | Dose Escalation: Incidence of Dose-limiting Toxicities (DLT), Treatment-emergent Adverse Events (TEAE), Serious Adverse Events (SAE), Adverse Events of Special Interest (AESI) |
| Registry ID | NCT04676477 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:30.540Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04676477
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.